Ideaya Biosciences IDYA shares are trading higher on Wednesday after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $21 per share.
Ideaya Biosciences an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It's engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Ideaya Biosciences shares traded up 7.57% to $14.07 on Wednesday. The stock has a 52-week high of $19.97 and a 52-week low of $2.95.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
